Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in Progress. (PubMed, Onco Targets Ther) - Oct 9, 2026 - P1/2 | "The study is actively enrolling at 17 sites in Italy, Spain and United Kingdom. Given the safety profile of roginolisib as monotherapy in patients of the FiH study, the combination of a JAK inhibitor (eg, ruxolitinib) and roginolisib is expected to provide a well-tolerated treatment in patients with MF who are no longer responding to JAK inhibition."
First-in-human • Journal • Myelofibrosis • PIK3CD
|
|
Alessandro Lucchesi; Alessandro Maria Vannucchi; Armando Santoro; Chiara Paoli; Ciro Rinaldi; Claire Harrison; Damián Cubillas García de la Torre; Daniela Cilloni; Fabrizio Pane; Francesca Palandri; Giuseppe Lanzarone; Giusy Di Conza; Graeme Greenfield; Jasson Villarreal Hernandez; Javier Octavio Díaz Carbonero; Jesús María Hernández-Rivas; Johanne Polasek; Karen M Tonge; María Laura Fox; Mario Tiribelli; Massimo Breccia; Matteo Pacilli; Michael Emig; Michael Lahn; Mireille Cantarini; Paola Guglielmelli; Paramjit Kaur; Priya Sriskandarajah; Tracey C Hammett
|